News

Summit Therapeutics Receives Fast Track Designation for Novel Antibiot


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Summit Therapeutics Receives Fast Track Designation for Novel Antibiotic SMT19969 for CDI


Date: 13/07/2015


Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and  

“Fast Track designation recognises the serious healthcare threat posed by 

For more click here

Source: OBN

© Catalyst Innovation Portal 2019